Publication:
Prognosis and Disease Activity

dc.contributor.authorsAlibaz-Oner F., Direskeneli H.
dc.date.accessioned2022-03-15T02:17:03Z
dc.date.accessioned2026-01-10T17:38:49Z
dc.date.available2022-03-15T02:17:03Z
dc.date.issued2021
dc.description.abstractCorrect assessment of the extent of arterial involvement, clinical activity and damage in Takayasu’s Arteritis (TAK) is essential for treatment or surgical intervention decisions during the disease course [1]. However, there are no widely accepted and validated definitions of “disease activity” or “response to treatment”. One of the major difficulties is the differentiation between ongoing activity and vascular damage in TAK. Vascular stenosis may occur as a result of active inflammation or be a sign of disease-related damage due to scarring in the vessel wall [2]. Atherosclerosis is another important clinical problem in the assessment of TAK, especially in patients having long-standing disease or normal acute-phase response. There is a clear need and ongoing efforts to develop a validated set of outcome measures for use in clinical trials of TAK. © 2021, Springer Nature Switzerland AG.
dc.identifier.doi10.1007/978-3-030-67175-4_11
dc.identifier.issn22826505
dc.identifier.urihttps://hdl.handle.net/11424/248276
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofRare Diseases of the Immune System
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDamage
dc.subjectDisease assessment
dc.subjectPrognosis
dc.titlePrognosis and Disease Activity
dc.typebookPart
dspace.entity.typePublication
oaire.citation.endPage130
oaire.citation.startPage119
oaire.citation.titleRare Diseases of the Immune System

Files